Development of a fed-batch process for the production of anticancer drug TATm-survivin(T34A) in Escherichia coli
- 1 October 2008
- journal article
- Published by Elsevier in Biochemical Engineering Journal
- Vol. 43 (2) , 163-168
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Influence of induction and operation mode on recombinant rhamnulose 1-phosphate aldolase production by Escherichia coli using the T5 promoterJournal of Biotechnology, 2005
- Optimised expression and purification of recombinant human indoleamine 2,3-dioxygenaseProtein Expression and Purification, 2004
- Secretory and extracellular production of recombinant proteins using Escherichia coliApplied Microbiology and Biotechnology, 2004
- Production of tilapia insulin-like growth factor-2 in high cell density cultures of recombinant Escherichia coliJournal of Biotechnology, 2004
- Tuning the Transcription Rate of Recombinant Protein in Strong Escherichiacoli Expression Systems through Repressor TitrationBiotechnology Progress, 2003
- Enhanced Production of Human Mini-Proinsulin in Fed-Batch Cultures at High Cell Density of Escherichia coli BL21(DE3)[pET-3aT2M2]Biotechnology Progress, 1997
- Fed‐batch feeding and induction policies that improve foreign protein synthesis and stability by avoiding stress responsesBiotechnology and Bioengineering, 1995
- High cell density fermentation of recombinant Vibrio cholerae for the production of B subunit of Escherichia coli enterotoxinBiotechnology and Bioengineering, 1995
- Effect of growth rate on stability and gene expression of recombinant plasmids during continuous and high cell density cultivation of Escherichia coli TG1Journal of Biotechnology, 1994
- Use of high density cultures of Escherichia coli for high level production of recombinant Pseudomonas aeruginosa exotoxin AApplied Microbiology and Biotechnology, 1991